-
公开(公告)号：US11623957B2
公开(公告)日：2023-04-11
申请号：US16489539
申请日：2016-12-07
Applicant: Xencor, Inc.
Inventor： Gregory Moore , John Desjarlais , Seung Chu
Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
-
公开(公告)号：US20230086017A1
公开(公告)日：2023-03-23
申请号：US17871829
申请日：2022-07-22
Applicant: Xencor, Inc.
Inventor： Gregory Moore , John Desjarlais , Seung Chu , Sung-Hyung Lee
IPC: C07K16/28
Abstract: Provided herein are trispecific antibodies that include a) a first monomer, b) a second monomer, and c) a light chain. The first monomer includes a first variant Fc domain and a variable heavy domain, the second monomer includes a second variant Fc domain and a first scFv domain and the light chain includes a variable light domain. The variable heavy domain and the variable light domain form an antigen binding domain. The trispecific antibody further includes a second scFv domain on either the first or second monomers.
-
公开(公告)号：US20200339624A1
公开(公告)日：2020-10-29
申请号：US16721356
申请日：2019-12-19
Applicant: Xencor, Inc.
Inventor： Seung Chu , Matthew Bernett , Dilki Wickramarachichi , John Desjarlais
Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
-
公开(公告)号：US10428155B2
公开(公告)日：2019-10-01
申请号：US14757809
申请日：2015-12-22
Applicant: Xencor, Inc.
Inventor： Gregory Moore , John Desjarlais , Seung Chu , Sung-Hyung Lee
IPC: C07K16/28
Abstract: The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
-
公开(公告)号：US20160355600A1
公开(公告)日：2016-12-08
申请号：US14757809
申请日：2015-12-22
Applicant: Xencor, Inc.
Inventor： Gregory Moore , John Desjarlais , Seung Chu , Sung-Hyung Lee
IPC: C07K16/28
CPC classification number: C07K16/2887 , C07K16/2803 , C07K16/2809 , C07K16/2815 , C07K16/2866 , C07K16/2896 , C07K2317/31 , C07K2317/52 , C07K2317/60 , C07K2317/622 , C07K2317/626
Abstract: The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
Abstract translation: 本发明提供与CD3，CD8和肿瘤靶抗原共同结合的三特异性抗体。
-
Patent Agency Ranking
公开(公告)号：US20230227581A1
公开(公告)日：2023-07-20
申请号：US17817334
申请日：2022-08-03
Applicant: Xencor, Inc.
Inventor： Rumana Rashid , Umesh S. Muchhal , Gregory Moore , Alex Nishtal , Seung Chu , Sung-Hyung Lee , Yoon Kyung Kim
CPC classification number: C07K16/40 , C07K16/2809 , C07K16/468 , C12N15/63 , C07K2317/565 , C07K2317/622
Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3).
-
公开(公告)号：US11225528B2
公开(公告)日：2022-01-18
申请号：US16354058
申请日：2019-03-14
Applicant: Xencor, Inc.
Inventor： Matthew J. Bernett , Gregory Moore , John Desjarlais , Seung Chu , Rumana Rashid , Umesh Muchhal , Sung-Hyung Lee
Abstract: The present invention is directed to novel heterodimeric antibodies.
-
公开(公告)号：US11111315B2
公开(公告)日：2021-09-07
申请号：US15945681
申请日：2018-04-04
Applicant: Xencor, Inc.
Inventor： Matthew J. Bernett , Gregory Moore , John Desjarlais , Seung Chu , Rumana Rashid , Umesh Muchhal , Sung-Hyung Lee
Abstract: The present invention is directed to novel heterodimeric antibodies.
-
公开(公告)号：US10982006B2
公开(公告)日：2021-04-20
申请号：US16375777
申请日：2019-04-04
Applicant: Xencor, Inc.
Inventor： John Desjarlais , Alex Nisthal , Seung Chu
Abstract: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
-
公开(公告)号：US10227411B2
公开(公告)日：2019-03-12
申请号：US15063441
申请日：2016-03-07
Applicant: Xencor, Inc.
Inventor： Matthew Bernett , Seung Chu , Dilki Wickramarachichi , John Desjarlais
Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.035 seconds)
